Aethlon Medical (NASDAQ: AEMD) raises ATM capacity to $542,716
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Aethlon Medical, Inc. updated its at-the-market equity program, allowing sales of common stock with an aggregate offering price of up to $542,716 under its existing agreement with H.C. Wainwright & Co. pursuant to an amended prospectus supplement.
This new capacity follows prior sales of common stock totaling $1,849,457 under the same prospectus. As of June 1, 2026, Aethlon had 2,344,886 shares of common stock outstanding, including 2,337,629 shares held by non-affiliates used to calculate its public float under Form S-3 rules.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
New ATM capacity: $542,716 aggregate offering price
Prior ATM sales: $1,849,457 aggregate sales price
Shares outstanding: 2,344,886 shares
+3 more
6 metrics
New ATM capacity
$542,716 aggregate offering price
Placement Shares available under amended prospectus supplement
Prior ATM sales
$1,849,457 aggregate sales price
Common stock previously sold under prospectus supplement
Shares outstanding
2,344,886 shares
Common stock outstanding as of June 1, 2026
Non-affiliate shares
2,337,629 shares
Held by non-affiliates for public float under Form S-3 I.B.6
Registration statement
Form S-3 File No. 333-292405
Became effective on January 2, 2026
Amendment filing date
June 4, 2026
Amendment No. 1 to prospectus supplement filed
Key Terms
At Market Offering Agreement, Prospectus Supplement, Registration Statement on Form S-3, General Instruction I.B.6 of Form S-3, +1 more
5 terms
At Market Offering Agreement financial
"pursuant to that certain At Market Offering Agreement, dated March 24, 2022"
Prospectus Supplement regulatory
"filed a prospectus supplement (the “Prospectus Supplement”) with the Securities and Exchange Commission"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
Registration Statement on Form S-3 regulatory
"under the Company's Registration Statement on Form S-3 (File No. 333-292405)"
A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.
General Instruction I.B.6 of Form S-3 regulatory
"update the amount of shares eligible for sale pursuant to General Instruction I.B.6 of Form S-3"
public float financial
"held by non-affiliates for purposes of calculating the Company's public float under General Instruction I.B.6 of Form S-3"
Public float is the total number of a company's shares that are available for trading by the general public. It excludes shares held by company insiders or large stakeholders who are unlikely to sell them easily. This figure helps investors understand how much of the company's stock is actively available, which can influence its liquidity and how easily its price might change.
FAQ
What change did Aethlon Medical (AEMD) make to its at-the-market offering?
Aethlon Medical increased the capacity of its at-the-market stock offering to allow sales of up to $542,716 of common stock. This update was implemented through Amendment No. 1 to its prospectus supplement filed on June 4, 2026.
How much stock has Aethlon Medical (AEMD) already sold under the ATM program?
Before the latest amendment, Aethlon Medical had already sold common stock with an aggregate sales price of $1,849,457 under the existing prospectus. The new $542,716 capacity is in addition to these previously completed at-the-market sales.